ESMO Guidance for Reporting Oncology real-World evidence (GROW)

L Castelo-Branco¹, A Pellat², D Martins-Branco³, A Valachis⁴, J W G Derksen⁵, K P M Suijkerbuijk⁶, U Dafni⁷, T Dellaporta⁸, A Vogel⁹, A Prelaj¹⁰, R H H Groenwold¹¹, H Martins¹², R Stahel¹³, J Bliss¹⁴, J Kather¹⁵, N Ribelles¹⁶, F Perrone¹⁷, P S Hall¹⁸, R Dienstmann¹⁹, C M Booth²⁰, G Pentheroudakis²¹, S Delaloge²², M Koopman⁶

Affiliations

¹ Scientific and Medical Division, European Society for Medical Oncology (ESMO), Lugano, Switzerland. Electronic address: luismocb@hotmail.com.
² Department of Gastroenterology and Digestive Oncology, Hôpital Cochin AP-HP, Université Paris Cité, Paris; Centre d'Épidémiologie Clinique, Hôtel Dieu, Paris, France.
³ Scientific and Medical Division, European Society for Medical Oncology (ESMO), Lugano, Switzerland; Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Academic Trials Promoting Team (ATPT), Brussels, Belgium.
⁴ Department of Oncology, Faculty of Medicine and Health, Örebro University Hospital, Örebro University, Örebro, Sweden.
⁵ Julius Center for Health Sciences and Primary Care, Department of Epidemiology and Health Economics, University Medical Centre Utrecht, Utrecht University, Utrecht.
⁶ Department of Medical Oncology, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.
⁷ Laboratory of Biostatistics, Department of Nursing, National and Kapodistrian University of Athens, Athens; Frontier Science Foundation Hellas, Athens, Greece.
⁸ Frontier Science Foundation Hellas, Athens, Greece.
⁹ Department of Gastroenterology, Hepatology and Endocrinology, Medical School of Hannover, Hannover, Germany; Toronto Center of Liver Disease, Toronto General Hospital, University Health Network, Toronto; Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
¹⁰ AI-ON-Lab, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, Milan; NEARLab, Department of Electronics, Information and Bioengineering, Politecnico di Milano, Milan, Italy.
¹¹ Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
¹² Business Research Unit, ISCTE Business School, ISCTE-IUL, Lisbon, Portugal.
¹³ ETOP IBCSG Partners Foundation, Berne, Switzerland.
¹⁴ ICR-CTSU, Division of Clinical Studies, The Institute of Cancer Research, London, UK.
¹⁵ Else Kroener Fresenius Center for Digital Health, Technical University Dresden, Dresden; Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
¹⁶ Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, Málaga, Spain.
¹⁷ Clinical Trial Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy.
¹⁸ Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
¹⁹ Oncoclinicas Precision Medicine, Oncoclinicas Group, São Paulo, Brazil; Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
²⁰ Department of Oncology; Department of Public Health Sciences, Queen's University, Kingston, Canada.
²¹ Scientific and Medical Division, European Society for Medical Oncology (ESMO), Lugano, Switzerland.
²² Department of Cancer Medicine, Gustave Roussy, Villejuif, France.

PMID: 37848160
DOI: 10.1016/j.annonc.2023.10.001

Free article

Practice Guideline

ESMO Guidance for Reporting Oncology real-World evidence (GROW)

L Castelo-Branco et al. Ann Oncol. 2023 Dec.

Free article

. 2023 Dec;34(12):1097-1112.

doi: 10.1016/j.annonc.2023.10.001. Epub 2023 Oct 15.

Authors

Affiliations

¹ Scientific and Medical Division, European Society for Medical Oncology (ESMO), Lugano, Switzerland. Electronic address: luismocb@hotmail.com.
² Department of Gastroenterology and Digestive Oncology, Hôpital Cochin AP-HP, Université Paris Cité, Paris; Centre d'Épidémiologie Clinique, Hôtel Dieu, Paris, France.
³ Scientific and Medical Division, European Society for Medical Oncology (ESMO), Lugano, Switzerland; Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Academic Trials Promoting Team (ATPT), Brussels, Belgium.
⁴ Department of Oncology, Faculty of Medicine and Health, Örebro University Hospital, Örebro University, Örebro, Sweden.
⁵ Julius Center for Health Sciences and Primary Care, Department of Epidemiology and Health Economics, University Medical Centre Utrecht, Utrecht University, Utrecht.
⁶ Department of Medical Oncology, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.
⁷ Laboratory of Biostatistics, Department of Nursing, National and Kapodistrian University of Athens, Athens; Frontier Science Foundation Hellas, Athens, Greece.
⁸ Frontier Science Foundation Hellas, Athens, Greece.
⁹ Department of Gastroenterology, Hepatology and Endocrinology, Medical School of Hannover, Hannover, Germany; Toronto Center of Liver Disease, Toronto General Hospital, University Health Network, Toronto; Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
¹⁰ AI-ON-Lab, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, Milan; NEARLab, Department of Electronics, Information and Bioengineering, Politecnico di Milano, Milan, Italy.
¹¹ Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
¹² Business Research Unit, ISCTE Business School, ISCTE-IUL, Lisbon, Portugal.
¹³ ETOP IBCSG Partners Foundation, Berne, Switzerland.
¹⁴ ICR-CTSU, Division of Clinical Studies, The Institute of Cancer Research, London, UK.
¹⁵ Else Kroener Fresenius Center for Digital Health, Technical University Dresden, Dresden; Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
¹⁶ Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, Málaga, Spain.
¹⁷ Clinical Trial Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy.
¹⁸ Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
¹⁹ Oncoclinicas Precision Medicine, Oncoclinicas Group, São Paulo, Brazil; Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
²⁰ Department of Oncology; Department of Public Health Sciences, Queen's University, Kingston, Canada.
²¹ Scientific and Medical Division, European Society for Medical Oncology (ESMO), Lugano, Switzerland.
²² Department of Cancer Medicine, Gustave Roussy, Villejuif, France.

PMID: 37848160
DOI: 10.1016/j.annonc.2023.10.001

No abstract available

Keywords: ESMO-GROW; guidance; observational studies; oncology; real-world data; real-world evidence.

PubMed Disclaimer

Publication types

Actions
Actions

MeSH terms

Actions
Actions

Grants and funding

25351/CRUK_/Cancer Research UK/United Kingdom

LinkOut - more resources

Full Text Sources
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

ESMO Guidance for Reporting Oncology real-World evidence (GROW)

Affiliations

ESMO Guidance for Reporting Oncology real-World evidence (GROW)

Authors

Affiliations

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources